{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":25,"n_cols":5,"rows_kept":25,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[7,2,7,3],[8,2,8,3],[10,2,10,3],[12,2,12,3],[13,2,13,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910144091303321"]
[null,null,"Titolo",null,"Anticancer therapeutics / / edited by Sotiris Missailidis"]
[null,null,"Pubbl/distr/stampa",null,"Chichester ; ; Hoboken, NJ, : John Wiley & Sons, 2008"]
[null,null,"ISBN",null,"1-281-93942-0"]
[{"$nulls":4},"9786611939427"]
[{"$nulls":4},"0-470-69704-0"]
[{"$nulls":4},"0-470-69703-2"]
[null,null,"Descrizione fisica",null,"1 online resource (426 p.)"]
[null,null,"Disciplina",null,"616.99/4061"]
[{"$nulls":4},"616.994061"]
[null,null,"Soggetti",null,"Cancer - Chemotherapy"]
[{"$nulls":4},"Antineoplastic agents"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Anticancer Therapeutics; Contents; Forward; Acknowledgements; List of contributors; SECTION I: Development of Anticancer Therapeutics; 1 Exploring the Potential of Natural Products in Cancer Treatment; 1.1 Introduction; 1.2 Sources; 1.3 Different Approaches to the Search for Bioactive Natural Products; 1.4 Methodologies of Lead Compound or New Drug Identification; 1.5 Chemoprevention - A New Area for Natural Product Research; 1.6 Concluding Remarks; 2 Combinatorial Approaches to Anticancer Drug Design; 2.1 Introduction; 2.2 Combinatorial Approaches for Small Molecule Drug Design"]
[{"$nulls":4},"2.3 Display Technologies2.4 Aptamer Selection; 2.5 Conclusions; 3 Rational Approaches to Anticancer Drug Design/in silico Drug Development; 3.1 Introduction; 3.2 Approaches to the Drug Discovery Process in Anticancer Research; 3.3 Ligand-based Examples; 3.4 Structure-based Examples; 3.5 Conclusions; SECTION II: Anticancer Therapeutics; 4 Introduction to Anticancer Therapeutics; 4.1 Problems in cancer; 4.2 Cancer treatments; 4.3 Classification of chemotherapy drugs; 5 Platinum Drugs; 5.1 Cisplatin; 5.2 Lipoplatin; 5.3 Carboplatin; 5.4 Oxaliplatin; 5.5 Lipoxal; 5.6 New Platinum Compounds"]
[{"$nulls":4},"5.7 Cisplatin Resistance and Chemotherapy6 Antimicrotubule Agents; 6.1 Taxanes; 6.2 Vinca Alkaloids; 6.3 Mechanisms of Resistance to Antimicrotubule Agents; 7 Antimetabolites in Cancer Therapy; 7.1 Introduction; 7.2 Folate Antagonists; 7.3 Pyrimidine Antagonists; 7.4 "]
[{"$nulls":4},"Purine Antagonists; 7.5 Summary; 8 Antitumour Antibiotics; 8.1 Introduction; 8.2 Actinomycin; 8.3 Mitomycin C; 8.4 Bleomycin; 8.5 Anthracyclines; 8.6 Trabectedin (Ecteinascidin, ET-743); 8.7 Camptothecins; 8.8 Podophyllotoxins; 9 Alkylating Agents; 9.1 Introduction; 9.2 Nitrogen Mustards; 9.3 Methylmelamines and Ethylenimines"]
[{"$nulls":4},"9.4 Methylhydrazine Derivatives9.5 Alkylsulfonates; 9.6 Nitrosoureas; 9.7 Triazenes; 10 Hormone Therapies; 10.1 Introduction; 10.2 Oestrogen Receptor Targeted Therapeutics; 10.3 Progesterone-Targeted Therapy; 10.4 Neuroendocrine Tumours; 11 Photodynamic Therapy of Cancer; 11.1 Introduction; 11.2 Photosensitizers; 11.3 Outlook; 11.4 Acknowledgement; 12 Target-directed Drug Discovery; 12.1 Introduction; 12.2 Tyrosine Kinases - Role and Significance in Cancer; 12.3 Targeted Therapy for the Treatment of Non-small Cell Lung Cancer (NSCLC)"]
[{"$nulls":4},"12.4 Targeted Therapy for the Treatment of Chronic Myeloid Leukaemia12.5 Targeted Therapy for the Treatment of Breast Cancer; 12.6 Angiogenesis; 12.7 Targeting Cell Cycling; 12.8 Targeting Apoptosis; 12.9 Targeting mTOR; 12.10 The Future of Molecularly Targeted Therapy; 13 Tumour Hypoxia: Malignant Mediator; 13.1 Introduction; 13.2 Hypoxia Inducible Factor-1 and Hypoxia; 13.3 HIF-1α Post-translational Changes; 13.4 How Genetics Can Modify HIF; 13.5 How Tumours Overcome Hypoxia with HIF-1; 13.6 HIF-1 Therapeutics; 13.7 Conclusion; 14 Resistance to Chemotherapy Drugs; 14.1 Introduction"]
[{"$nulls":4},"14.2 What are the Factors Limiting the Efficacy of Cancer Chemotherapy Treatment?"]
[null,null,null,"Sommario/riassunto","Written by the winner of the 2008 Mike Price Fellowship \"\"This volume provides a comprehensive overview of the wealth of information now available in this important and fast-moving subject.\"\" Anticancer Research, November - December 2008 This book provides a clear introduction to the area, with an overview of the various drug design and development approaches for cancer therapeutics and their progress in today's multidisciplinary approach to cancer treatment. Clearly structured throughout, the book not only provides information on currently used molecular treatment a"]